Coforge stock split: Coforge share price climbed 2 per cent on ex-date for stock split; Check more details here
Following recent announcements regarding corporate action such as dividends, bonus issues, and rights issues, drawing attention from investors
IT stocks jumped in trade after a US federal court on Wednesday (local time) blocked President Donald Trump from imposing broad tariffs on imports under an emergency-powers law.
Coforge and Vesuvius have rallied up to 29% post announcement of stock split; technical charts suggest these 2 stocks could rally another 16% from present levels.
Here is the complete list of stocks that will remain in the spotlight during trading sessions following their dividend announcements to shareholders as they go ex-date on Friday, May 9, 2025
While overall FY25 order flow stood at $3.4 billion, up 75 per cent year-on-year (Y-o-Y), about $2.1 billion came in Q4 alone
Despite travel market weakness and global macroeconomic concerns, Coforge expects BFSI, insurance and Gen AI-led deals to sustain strong momentum in FY26
Coforge share price: The company's revenue from operations increased 4.6 per cent to ₹3,409.9 crore as compared to ₹3,258.1 crore in Q3
IT solutions firm Coforge on Monday reported a 16.5 per cent increase in consolidated net profit to Rs 261 crore in the March quarter. It had posted a net profit (attributable to owners of Coforge Ltd) of Rs 224 crore in the year-ago period, according to a regulatory filing. Revenue from operations for the quarter under review rose 47 per cent year-on-year to reach Rs 3,410 crore, against Rs 2,318 crore in Q4 FY24. Seen sequentially, profit and revenue rose 21 per cent and 4.6 per cent, respectively. The firm's order intake in Q4 FY25 stood at USD 2.1 billion. It signed five large deals during the quarter, across North America, the UK, and APAC. For the full fiscal year, profit saw a marginal increase, from Rs 808 crore in FY24 to Rs 812 crore in FY25. Revenue in FY25 climbed 33.7 per cent to Rs 12,051 crore in FY25, from Rs 9,009 crore in the previous fiscal year. All financial figures are based on continuing operations -- excluding the AdvantageGo business that Coforge diveste
Q4 FY25 company results today: M&M, Coforge, Computer Age Management Services will be among 47 companies to post earnings reports for the January-March quarter on May 5
Motilal Oswal Mutual Fund (MF) on Thursday acquired additional shares of IT firm Coforge worth Rs 231 crore through an open market transaction. According to the bulk deal data available on the NSE, Motilal Oswal MF purchased 3.5 lakh shares or 0.52 per cent stake in Greater Noida-based Coforge. The shares were acquired at an average price of Rs 6,605.13 apiece, taking the transaction value to Rs 231.18 crore. After the latest transaction, Motilal Oswal MF's equity stake in Coforge rose to 8.58 per cent from 8.06 per cent. Details of the seller(s) of Coforge's shares could not be ascertained on the National Stock Exchange (NSE). The scrip of Coforge on Thursday climbed 3.78 per cent to close at Rs 6,650 per piece on the NSE. On Thursday, Coforge said its wholly-owned subsidiary Coforge Technologies Australia has completed the acquisition of TMLabs from its shareholders in accordance with the share sale agreement.
The Nifty IT index plunged amid recession-related fears due to US imposing 'reciprocal tariffs' on trading partners without showing signs of backing down
The downturn in IT stocks can be attributed to fears around recession and as manufacturing hubs in China and Taiwan face new tariffs above 30 per cent
Sumit Pokharna, vice president for fundamental research at Kotak Securities suggests five IT stocks that investors can still bet upon from a long-term perspective
The intraday rise, one of the highest for the mid-tier IT services company, came on a day when the broader BSE Information Technology index also rose 2 per cent
In the board meeting, a stock split was approved in a 1:5 ratio i.e. existing equity shares of face value of Rs 10 each will be split into 33,43,65,495 shares of face value of Rs 2
Biocon: The company's subsidiary, Biocon Pharma, has received USFDA approvals for Lenalidomide capsules and Dasatinib tablets, and tentative approval for Rivaroxaban tablets
The deal is significant at a time when large IT services players have noted that deal sizes from clients are getting smaller with shorter time frames
The drop in the company's share price aligns with the dividend announcement it has made for its shareholders, as the company's shares trade ex-dividend today
Why are midcap IT stocks rising today: Persistent Systems share price soared 8 per cent to Rs 6,163.45 per share after the company reported broad-based growth across geographies and segments.